Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1636651 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $2.29Day −2.97%Mkt cap $427M1Y +324.1%Off 52W high −26.2%Vol (1Y) 107.9%
Daily closing price, split-adjusted to the current basis; 3y shown of 2,315 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest11.8% of sh out |
| Days to cover12.7d |
| 13F net flow (QoQ)+12.85% |
| Top-10 13F concentration67.8% |
| Next report (est.)2026-08-11 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$7.1M |
| Earnings (TTM)-$24.2M |
| ROE−17.5% |
| Net margin−240.1% |
| ROIC−42.1% |
| Sales growth 3Y69.0% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+40.5% |
| 1Y+324.1% |
| 3Y−36.2% |
| 5Y−39.1% |
| Since incept. (ann.)−16.6% |
Total return through 2026-07-29 · series begins 2017-05-05. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)107.9% |
| Ann. volatility (3Y)97.2% |
| Sharpe (1Y)1.88 |
| Sharpe (3Y)0.45 |
| Max drawdown (1Y)−34.8% |
| Max drawdown (3Y)−93.7% |
| Beta (3Y vs SPY)0.35 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 10.7M | $24M | 5.74% | +0.0% |
| JANUS HENDERSON GROUP PLC | 10.7M | $24M | 5.74% | new |
| Affinity Asset Advisors, LLC | 10.6M | $24M | 5.70% | +48.8% |
| EVENTIDE ASSET MANAGEMENT, LLC | 9.9M | $22M | 5.31% | +131.4% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 6.2M | $14M | 3.30% | +76.5% |
| Balyasny Asset Management L.P. | 5.5M | $12M | 2.96% | +1602.5% |
| VANGUARD CAPITAL MANAGEMENT LLC | 5.3M | $12M | 2.82% | new |
| ADAR1 Capital Management, LLC | 4.5M | $10M | 2.43% | +6.0% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-12 | — | — | $0 | −100.0% |
| 2025-12-31 | 2026-03-18 | — | — | $718,000 | +844.7% |
| 2025-09-30 | 2025-11-12 | — | — | $132,000 | −23.7% |
| 2025-06-30 | 2025-08-13 | — | — | $6.3M | +3611.2% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-11 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
Reportable 100%
business segments · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
